[{"id":"136a071c-a450-44c3-b7aa-6d3862e474ed","acronym":"TSEBT","url":"https://clinicaltrials.gov/study/NCT02542124","created_at":"2021-01-29T07:10:44.367Z","updated_at":"2024-07-02T16:37:05.245Z","phase":"Phase 2","brief_title":"NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)","source_id_and_acronym":"NCT02542124 - TSEBT","lead_sponsor":"Neumedicines Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HemaMax (rHuIL-12)"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2018-11-16"},{"id":"182eb3d5-4d3b-4709-b9e1-b6f19bd522bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544724","created_at":"2021-01-18T12:18:42.002Z","updated_at":"2024-07-02T16:37:30.035Z","phase":"Phase 2","brief_title":"NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy","source_id_and_acronym":"NCT02544724","lead_sponsor":"Neumedicines Inc.","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HemaMax (rHuIL-12)"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2016-08-03"}]